PMID- 16125510
OWN - NLM
STAT- MEDLINE
DCOM- 20050922
LR  - 20171116
IS  - 0002-9343 (Print)
IS  - 0002-9343 (Linking)
VI  - 118 Suppl 8A
DP  - 2005 Aug
TI  - Anticoagulants in the treatment of deep vein thrombosis.
PG  - 13S-20S
AB  - Intravenous (IV) infusion of unfractionated heparin (UFH) followed by oral 
      administration of warfarin remains the cornerstone of clinical treatment of deep 
      vein thrombosis (DVT). Results from numerous clinical trials demonstrate that 
      subcutaneously administered low-molecular-weight heparin (LMWH) is at least as 
      effective and as safe as IV UFH. Treatment with LMWH has several clinical 
      advantages over treatment with UFH, including less-frequent dosing and 
      elimination of the need for monitoring. The introduction of LMWHs has made it 
      possible for physicians to offer outpatient treatment of DVT, with the associated 
      advantage of reduced costs due to shortened hospital stays. However, the optimal 
      duration of anticoagulant therapy after DVT is still debated, as it depends on an 
      individual patient's potential risk for recurrence or treatment-associated 
      complications. Patients are usually risk stratified on the basis of multiple 
      clinical characteristics, including the location of thromboemboli, the presence 
      or absence of cancer, the assumed etiology or cause of DVT (idiopathic vs. due to 
      a transient risk factor), and the presence of certain thrombophilic conditions. 
      High-risk patients often receive inpatient treatment with UFH or LMWH and are 
      candidates for long-term (> or = 6 months) oral anticoagulation, whereas 
      short-term anticoagulation (3 to 6 months) is usually indicated for patients who 
      are at lower risk of recurrence or therapeutic complications and who can be 
      treated with LMWH on an outpatient basis. The introduction of LMWHs has resulted 
      in significant clinical progress for the treatment of DVT.
FAU - Merli, Geno
AU  - Merli G
AD  - Jefferson Antithrombotic Therapy Service, Division of Internal Medicine, Thomas 
      Jefferson University Hospital, Jefferson Medical College, Philadelphia, 
      Pennsylvania 19107, USA. geno.merli@jefferson.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Med
JT  - The American journal of medicine
JID - 0267200
RN  - 0 (Anticoagulants)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Ambulatory Care
MH  - Anticoagulants/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Contraindications
MH  - Drug Administration Schedule
MH  - Heparin/therapeutic use
MH  - Hospitalization
MH  - Humans
MH  - Venous Thrombosis/*drug therapy
MH  - Warfarin/therapeutic use
RF  - 44
EDAT- 2005/08/30 09:00
MHDA- 2005/09/24 09:00
CRDT- 2005/08/30 09:00
PHST- 2005/08/30 09:00 [pubmed]
PHST- 2005/09/24 09:00 [medline]
PHST- 2005/08/30 09:00 [entrez]
AID - S0002-9343(05)00441-9 [pii]
AID - 10.1016/j.amjmed.2005.06.006 [doi]
PST - ppublish
SO  - Am J Med. 2005 Aug;118 Suppl 8A:13S-20S. doi: 10.1016/j.amjmed.2005.06.006.